Jinhe Net Income From Continuing Ops from 2010 to 2025

002688 Stock   4.33  0.03  0.69%   
Jinhe Biotechnology's Net Income From Continuing Ops is decreasing over the years with stable fluctuation. Overall, Net Income From Continuing Ops is expected to go to about 109.2 M this year. From 2010 to 2025 Jinhe Biotechnology Net Income From Continuing Ops quarterly data regression line had arithmetic mean of  125,094,020 and r-squared of  0.01. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2018-06-30
Previous Quarter
43 M
Current Value
22.5 M
Quarterly Volatility
27 M
 
Covid
Check Jinhe Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jinhe Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 20.8 M, Selling General Administrative of 167.5 M or Total Revenue of 1.5 B, as well as many indicators such as . Jinhe financial statements analysis is a perfect complement when working with Jinhe Biotechnology Valuation or Volatility modules.
  
This module can also supplement various Jinhe Biotechnology Technical models . Check out the analysis of Jinhe Biotechnology Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jinhe Stock

Jinhe Biotechnology financial ratios help investors to determine whether Jinhe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jinhe with respect to the benefits of owning Jinhe Biotechnology security.